Century Therapeutics Business Summary

Century Therapeutics, Inc. (IPSC) is a clinical-stage biotechnology company that generates revenue primarily through strategic collaboration and licensing agreements with major pharmaceutical partners, such as Bayer and previously Bristol Myers Squibb. The company operates through two primary business segments: Immuno-oncology, focusing on hematologic and solid tumors, and Autoimmune Diseases, including systemic lupus erythematosus and type 1 diabetes. Its proprietary platform utilizes induced pluripotent stem cells (iPSCs) and CRISPR-mediated gene editing to develop off-the-shelf, allogeneic cell therapies, notably featuring its Allo-Evasion technology designed to prevent host immune rejection. Century competes directly with Fate Therapeutics, BlueRock Therapeutics (Bayer), and Nkarta, positioning itself as a leader in the next-generation iPSC space by offering standardized, mass-produced therapeutic products that bypass the logistical and cost constraints of patient-derived CAR-T therapies. Century was founded in 2018 by venture firm Versant Ventures alongside scientific pioneers Dr. Marcela Maus of Harvard/MGH and Dr. Hiro Nakauchi of Stanford, with Lalo Flores serving as the founding CEO. The current leadership team is led by CEO and Board Chair Brent Pfeiffenberger, PharmD, MBA, who previously served as COO of Neogene Therapeutics and spent nearly two decades at Bristol Myers Squibb. The executive suite includes Chief Scientific Officer Dr. Chad Cowan, a co-founder of CRISPR Therapeutics and Sana Biotechnology, and Chief Financial Officer Dr. Morgan Conn, formerly of Pharvaris. Technical operations are overseen by Chief Technology and Manufacturing Officer Dr. Greg Russotti, an industry veteran from Celgene. The company is backed by a high-profile investor syndicate including TCGX, RA Capital Management, Casdin Capital, and Leaps by Bayer, recently securing a $135 million private placement in January 2026 to extend its clinical runway.